The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 8 November 2005, www.theannals.com, DOI 10.1345/aph.1E638.
The Annals of Pharmacotherapy: Vol. 39, No. 12, pp. 2056-2063. DOI 10.1345/aph.1E638
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, M. M
Right arrow Articles by Nathan, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, M. M
Right arrow Articles by Nathan, R. A

ALLERGY

Treatment for Allergic Rhinitis and Chronic Idiopathic Urticaria: Focus on Oral Antihistamines

Matthew M Morgan, MD1, David A Khan, MD2, and Robert A Nathan, MD3

1 Allergy, Asthma and Immunology of North Texas, McKinnney, TX
2 Associate Professor of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX
3 Clinical Professor of Medicine, Department of Allergy and Immunology, University of Colorado Health Sciences Center, Colorado Springs, CO

Reprints: Dr. Nathan, Department of Allergy and Immunology, University of Colorado Health Sciences Center, 2709 N. Tejon St., Colorado Springs, CO 80907-6237, fax 719/630-0688, drrnathan{at}aol.com

OBJECTIVE: To review the efficacy and safety of first- and newer-generation antihistamines for the management of allergic rhinitis and chronic idiopathic urticaria (CIU), with a focus on management in the pharmacy.

DATA SOURCES: A literature review was performed using MEDLINE (1966-October 2005), with no time or language restrictions. Key words or phrases used were histamine, antihistamine(s), first- and second-generation, allergic rhinitis, chronic idiopathic urticaria, quality of life, impairment, sedation, cost-effectiveness, astemizole, cetirizine, desloratadine, diphenhydramine, fexofenadine, loratadine, hydroxyzine, ketotifen, and mizolastine. Additional references were found in the bibliographies of the articles cited.

STUDY SELECTION AND DATA EXTRACTION: Clinical trials and other experimental studies of the use of antihistamines for the management of allergic rhinitis and CIU were selected. Review papers and guidelines were also included.

DATA SYNTHESIS: First-generation antihistamines are effective at ameliorating the symptoms of allergic rhinitis and CIU; however, they are associated with adverse effects due to a lack of selectivity for the histamine H1-receptor and an ability to bind to cerebral H1-receptors. Newer-generation agents, in general, possess high H1-receptor selectivity and a low tendency to cross the blood-brain barrier, while maintaining efficacy. In general, safety at elevated doses has been demonstrated for the newer antihistamines, although higher rates of sedation and impairment have been reported with increasing doses for some agents.

CONCLUSIONS: Pharmacists can play an important role in the management of allergic rhinitis and CIU by considering the relative advantages of newer-generation agents when reviewing treatment options.

Key Words: allergic rhinitis, antihistamine(s), chronic idiopathic urticaria

Published Online, November 8, 2005. www.theannals.com, DOI 10.1345/aph.1E638

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER :
407-000-05-036-H01


This article has been cited by other articles:


Home page
Annals of Clinical & Laboratory ScienceHome page
P. L. Zhang, J. R. Pennington, J. W. Prichard, T. M. Blasick, A. M. Brown, and S. Potdar
CD52 Antigen May Be a Therapeutic Target for Eosinophilic Rhinosinusitis
Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 148 - 151.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.